A M Fiksinski1, E J Breetvelt2, S N Duijff3, A S Bassett4, R S Kahn3, J A S Vorstman3. 1. Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands; Dalglish Family Hearts and Minds Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Electronic address: a.m.fiksinski@umcutrecht.nl. 2. Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands; Dalglish Family Hearts and Minds Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 3. Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Dalglish Family Hearts and Minds Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Individuals with 22q11.2 deletion syndrome (22q11DS) have a 25% risk for schizophrenia and related psychotic disorders. Some have hypothesized that Autism Spectrum Disorders (ASDs) diagnosed in children with 22q11DS may actually represent the social-communicative defects often observed during the early developmental stages of schizophrenia. METHODS: We prospectively studied 89 children with 22q11DS to test this hypothesis. At baseline, the Autism Diagnostic Interview was used to assess ASD, evaluating both current and early childhood behaviors. At follow-up, the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) was used to determine development of a psychotic disorder or psychotic symptoms. RESULTS: The average age (±SD) at first and last assessments was 14.3±1.9 and 19.0±3.0years, respectively. Nineteen (21.3%) children developed a psychotic disorder. Contrary to our hypothesis, there was no significant difference in the proportion that developed a psychotic disorder, comparing those with (n=9, 17.3%) and those without ASD at baseline (n=10, 27%; OR=0.500, 95% CI=0.160-1.569, p=0.235). Similar results were obtained using autistic symptom severity as quantitative predicting variable, psychotic symptoms as the outcome, and when correcting for age, gender and full scale IQ. CONCLUSION: Results indicate that in children with 22q11DS, early childhood autistic features are not associated with an increased risk for subsequent development of psychotic disorders or symptoms, replicating previous retrospective findings in adults with 22q11DS. These results indicate that ASD and psychotic disorders can emerge independently, as pleiotropic phenotypes in the context of 22q11DS.
BACKGROUND: Individuals with 22q11.2 deletion syndrome (22q11DS) have a 25% risk for schizophrenia and related psychotic disorders. Some have hypothesized that Autism Spectrum Disorders (ASDs) diagnosed in children with 22q11DS may actually represent the social-communicative defects often observed during the early developmental stages of schizophrenia. METHODS: We prospectively studied 89 children with 22q11DS to test this hypothesis. At baseline, the Autism Diagnostic Interview was used to assess ASD, evaluating both current and early childhood behaviors. At follow-up, the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) was used to determine development of a psychotic disorder or psychotic symptoms. RESULTS: The average age (±SD) at first and last assessments was 14.3±1.9 and 19.0±3.0years, respectively. Nineteen (21.3%) children developed a psychotic disorder. Contrary to our hypothesis, there was no significant difference in the proportion that developed a psychotic disorder, comparing those with (n=9, 17.3%) and those without ASD at baseline (n=10, 27%; OR=0.500, 95% CI=0.160-1.569, p=0.235). Similar results were obtained using autistic symptom severity as quantitative predicting variable, psychotic symptoms as the outcome, and when correcting for age, gender and full scale IQ. CONCLUSION: Results indicate that in children with 22q11DS, early childhood autistic features are not associated with an increased risk for subsequent development of psychotic disorders or symptoms, replicating previous retrospective findings in adults with 22q11DS. These results indicate that ASD and psychotic disorders can emerge independently, as pleiotropic phenotypes in the context of 22q11DS.
Authors: Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou Journal: Int J Dev Neurosci Date: 2010-10-08 Impact factor: 2.457
Authors: Jacob A S Vorstman; Eva W Chow; Roel A Ophoff; Herman van Engeland; Frits A Beemer; René S Kahn; Richard J Sinke; Anne S Bassett Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-04-05 Impact factor: 3.568
Authors: Anne S Bassett; Eva W C Chow; Janice Husted; Rosanna Weksberg; Oana Caluseriu; Gary D Webb; Michael A Gatzoulis Journal: Am J Med Genet A Date: 2005-11-01 Impact factor: 2.802
Authors: Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett Journal: Am J Med Genet A Date: 2018-05-19 Impact factor: 2.802
Authors: Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman Journal: Am J Med Genet A Date: 2018-09-08 Impact factor: 2.802
Authors: Jacob Vorstman; Elemi J Breetvelt; Ania M Fiksinski; Carrie E Bearden; Anne S Bassett; René S Kahn; Janneke R Zinkstok; Stephen R Hooper; Wanda Tempelaar; Donna McDonald-McGinn; Ann Swillen; Beverly Emanuel; Bernice Morrow; Raquel Gur; Eva Chow; Marianne van den Bree; Joris Vermeesch; Stephen Warren; Michael Owen; Therese van Amelsvoort; Stephan Eliez; Doron Gothelf; Celso Arango; Wendy Kates; Tony Simon; Kieran Murphy; Gabriela Repetto; Damian Heine Suner; Stefano Vicari; Joseph Cubells; Marco Armando; Nicole Philip; Linda Campbell; Sixto Garcia-Minaur; Maude Schneider; Vandana Shashi Journal: Neuropsychopharmacology Date: 2021-03-29 Impact factor: 8.294
Authors: M Gudbrandsen; E Daly; C M Murphy; R H Wichers; V Stoencheva; E Perry; D Andrews; C E Blackmore; M Rogdaki; L Kushan; C E Bearden; D G M Murphy; M C Craig; C Ecker Journal: Cereb Cortex Date: 2019-07-22 Impact factor: 5.357
Authors: Avery B Albert; Tamara Abu-Ramadan; Wendy R Kates; Wanda Fremont; Kevin M Antshel Journal: J Int Neuropsychol Soc Date: 2018-10 Impact factor: 2.892
Authors: Maria Gudbrandsen; Caroline Mann; Anke Bletsch; Eileen Daly; Clodagh M Murphy; Vladimira Stoencheva; Charlotte E Blackmore; Maria Rogdaki; Leila Kushan; Carrie E Bearden; Declan G M Murphy; Michael C Craig; Christine Ecker Journal: Cereb Cortex Date: 2020-09-03 Impact factor: 5.357